Physician profile
David M Marks
NPI 1760499933
$2,042.99
in general payments reported to CMS, 2019-2025
20 companies · $1,998 in 2025
The $1,998 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $45.04 · 2025: $1,998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,042.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $499.91 | 2025 | Caplyta |
| Abbvie INC. | $293.84 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $215.51 | 2025 | Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $183.09 | 2024-2025 | Spravato |
| Vanda Pharmaceuticals INC. | $173.14 | 2025 | Fanapt, Hetlioz |
| Pfizer INC. | $117.20 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $93.24 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $79.32 | 2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $57.97 | 2025 | Belbuca |
| Lundbeck LLC | $52.08 | 2025 | Rexulti, Vyepti |
| Vertex Pharmaceuticals Incorporated | $42.17 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $40.09 | 2025 | Rejoyn |
| Lilly USA, LLC | $36.71 | 2025 | Zepbound |
| Alnylam Pharmaceuticals INC. | $35.80 | 2025 | Givlaari |
| Valinor Pharma, LLC | $24.17 | 2025 | Movantik |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.56 | 2025 | Relistor |
| Neurocrine Biosciences, INC. | $21.39 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $20.77 | 2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $18.99 | 2025 | Trintellix |
| Axsome Therapeutics, INC. | $16.04 | 2025 | Symbravo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Marks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.